secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2022-07-08T23:59:59+00:00
Accession:  0001193125-22-190006
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Kymera appoints Leigh Morgan to Board of Directors and Compensation Committee
-----------------------------------------------------------------------------

- Leigh Morgan appointed as Class II director effective July 6, 2022; term expires at 2025 annual meeting.
- Board determined she is independent under Nasdaq listing standards.
- Ms. Morgan also appointed to Compensation Committee; committee now includes Morgan, Albers, Maraganore, Nicholson.
- She will receive standard non-employee director compensation; no material transactions disclosed.
- No changes to Audit or Nominating and Corporate Governance Committees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312522190006/0001193125-22-190006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312522190006/d550029d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-190006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer